预约演示
更新于：2025-04-30
Fluticasone propionate/Salmeterol xinafoate
丙酸氟替卡松/昔萘酸沙美特罗
更新于：2025-04-30
概要
基本信息
药物类型 小分子化药 |
别名 Salmeterol Xinafoate/Fluticasone Propionate、Salmeterol/Fluticasone Propionate、Synflutide + [32] |
作用方式 激动剂 |
作用机制 GR激动剂(糖皮质激素受体激动剂)、cPLA2α 激动剂(胞内磷脂酶A2 激动剂)、β2-adrenergic receptor激动剂(β2-肾上腺素能受体激动剂) |
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C25H31F3O5S |
InChIKeyWMWTYOKRWGGJOA-CENSZEJFSA-N |
CAS号80474-14-2 |
查看全部结构式(2)
关联
272
项与 丙酸氟替卡松/昔萘酸沙美特罗 相关的临床试验CTR20244821
沙美特罗替卡松粉吸入剂在健康人空腹状态下的生物等效性试验
NCT06676319
A Randomized, Phase 2, Double-blind, Placebo-controlled, Parallel-group, 2-arm Study to Investigate the Efficacy, Safety, and Tolerability of Subcutaneous Lunsekimig (SAR443765) in Adult Participants With High-risk Asthma Who Are Not Currently Eligible for Biologic Treatment
CTR20244110
沙美特罗替卡松吸入粉雾剂在中国成年健康受试者中的一项单中心、随机、开放、空腹单次给药生物等效性试验
100 项与 丙酸氟替卡松/昔萘酸沙美特罗 相关的临床结果
登录后查看更多信息
100 项与 丙酸氟替卡松/昔萘酸沙美特罗 相关的转化医学
登录后查看更多信息
100 项与 丙酸氟替卡松/昔萘酸沙美特罗 相关的专利（医药）
登录后查看更多信息
692
项与 丙酸氟替卡松/昔萘酸沙美特罗 相关的文献（医药）2025-05-01INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
Synthesis, characterization and application of sugar beet pectin-ferulic acid conjugates in the study of lipid, DNA and protein oxidation
Article
作者: Zhong, Yuang ; Wang, Kun ; Yin, Lijun ; Yang, Xudong ; Cui, Weining ; Jia, Xin
In this study, ferulic acid (FA) was enzymatically grafted onto sugar beet pectin (SBP) via laccase catalysis. Structural characterization of sugar beet pectin-ferulic acid conjugates (SFC) with varying substitution degrees was performed using UV-vis, FT-IR, and NMR analyses. Mechanistic analyses revealed that phenolic hydroxyl groups (-OH) on FA reacted with carboxyl groups (-COOH) of SBP via enzymatic catalysis, forming covalent linkages. Additionally, amide bond formation between FA's carboxyl groups and amino groups (-NH₂) of pectin-associated proteins was observed. Compared to unmodified pectin, SFC exhibited reduced crystallinity, lower apparent viscosity, and smoother surfaces, whereas thermal stability and in vitro antioxidant capacity were markedly improved. Notably, SFC with high substitution (>159.60 ± 0.60 mg/g) effectively inhibited malondialdehyde (92.18 %) and peroxide (61.29 %) formation in linoleic acid oxidation systems, while demonstrating DNA (66.07 %) and protein (17.79 %) oxidation inhibition through reduced carbonyl generation. These findings highlight SFC's potential as a multifunctional antioxidant in food and pharmaceutical applications.
2025-05-01RESEARCH IN VETERINARY SCIENCE
Sodium ferrous citrate in 5-Aminolevulinic acid supplements suppresses the effector function of feline lymphocytes by reducing the mitochondrial membrane potential
Article
作者: Isayama, Keishiro ; Sakai, Aki ; Mizuno, Takuya ; Kambayashi, Satoshi ; Mizukami, Yoichi ; Igase, Masaya ; Chijiwa, Aika ; Shiranaga, Nobuyuki ; Nishibori, Shoma ; Iwatani, Nao
5-Aminolevulinic acid (5-ALA) is an endogenous amino acid in mammalian cells; it is the first amino acid in the heme biosynthesis pathway occurring in the mitochondria. 5-ALA with sodium ferrous citrate (SFC) possesses anti-inflammatory properties by inducing heme oxygenase (HO)-1 expression and releasing heme metabolites in humans and mice. Supplements containing 5-ALA and divalent iron is available in veterinary medicine. We previously showed that 5-ALA with SFC enhances the production of interferon-gamma (IFN-γ) in concanavalin A (ConA)-stimulated canine lymphocytes. However, the effects of 5-ALA/SFC on feline lymphocytes remain to be investigated. This study demonstrated that 5-ALA/SFC-induced HO-1 expression and decreased IFN-γ production in ConA-stimulated feline lymphocytes. Comprehensive RNA sequencing analysis revealed that the activating transcription factor 4 (ATF4) signaling pathway was inhibited by adding 5-ALA/SFC. Moreover, we confirmed that 5-ALA/SFC decreased ATF4 protein expression. Furthermore, separate analyses of the effects of 5-ALA and SFC on feline lymphocytes revealed that SFC, but not 5-ALA, induced AKT dephosphorylation and mitochondrial dysfunction in activated lymphocytes. Thus, SFC in 5-ALA supplements may suppress the effector function of feline lymphocytes via mitochondrial metabolism, thereby representing a novel mechanism in 5-ALA/SFC research.
2025-04-24BIOLOGICAL & PHARMACEUTICAL BULLETIN
Delayed Upper Gastrointestinal Motility in Mice Treated with Oral Iron Tablets
Article
作者: Mihara, Taiki ; Hori, Masatoshi ; Kurosawa, Tamaki ; Yamada, Syunki ; Maruyama, Aya ; Mitobe, Yuko ; Ohashi-Doi, Katsuyo
Oral iron preparations for iron deficiency anemia have major side effects, such as nausea and vomiting, which are gastrointestinal symptoms widely known to occur with gastrointestinal motility disorders. However, it is unclear whether these symptoms are associated with gastrointestinal motility. This study aimed to explore the correlation between oral iron preparations that cause nausea and vomiting with gastrointestinal motility. Sodium ferrous citrate (SFC), a common ingredient in iron preparations, was used in this study. Gastrointestinal motility in mice was measured using the 13C-octanoic acid breath test to determine gastric emptying and colonic transport capacities using the bead expulsion test. SFC significantly delayed gastric emptying. However, it did not affect the colonic transport capacity. Treatment with the antiemetic palonosetron, a 5-hydroxytryptamine 3 (5-HT3) receptor inhibitor, abolished the gastric evacuation retardation effect of SFC. However, the additive in the SFC formulation, palonosetron alone, did not affect the gastric emptying capacity. These results suggest that iron preparations cause vagal nausea and vomiting in the upper gastrointestinal tract due to chemical stimulation of the gastrointestinal blood with a concomitant reduction in gastric emptying capacity. Knowledge of the association of delayed gastric emptying with the onset of iron-induced nausea is useful for understanding iron-induced adverse effects.
153
项与 丙酸氟替卡松/昔萘酸沙美特罗 相关的新闻（医药）2025-04-13
·信狐药迅
疫苗信使RNA申请上市上市批准临床申请
2025-04-13
·药通社
上市批准一致性评价
2025-04-12
·米内网
一致性评价上市批准
100 项与 丙酸氟替卡松/昔萘酸沙美特罗 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 气道阻塞 | 美国 | 2008-04-30 | |
| 慢性支气管炎 | 日本 | 2007-04-18 | |
| 肺气肿 | 日本 | 2007-04-18 | |
| 哮喘 | 美国 | 2000-08-24 | |
| 慢性阻塞性肺疾病 | 美国 | 2000-08-24 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 闭塞性细支气管炎 | 临床3期 | 法国 | 2021-05-21 | |
| 持续性哮喘 | 临床3期 | 美国 | 2007-02-01 | |
| 持续性哮喘 | 临床3期 | 澳大利亚 | 2007-02-01 | |
| 持续性哮喘 | 临床3期 | 加拿大 | 2007-02-01 | |
| 持续性哮喘 | 临床3期 | 智利 | 2007-02-01 | |
| 持续性哮喘 | 临床3期 | 哥斯达黎加 | 2007-02-01 | |
| 持续性哮喘 | 临床3期 | 德国 | 2007-02-01 | |
| 持续性哮喘 | 临床3期 | 拉脱维亚 | 2007-02-01 | |
| 持续性哮喘 | 临床3期 | 立陶宛 | 2007-02-01 | |
| 持续性哮喘 | 临床3期 | 墨西哥 | 2007-02-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 427 | 觸齋膚範願廠鹹願選簾 = 壓獵觸齋窪膚餘鹹醖鹹 觸壓壓壓網壓製糧鏇壓 (積窪遞艱淵憲鹽積鑰廠, 積鬱憲構艱憲鏇築鹹構 ~ 觸顧齋鑰積選襯鏇構醖) 更多 | - | 2023-03-14 | |||
N/A | 慢性阻塞性肺疾病 维持 | 195 | Budesonide/Formoterol MART | 製齋壓鹽積簾鹽蓋淵糧(繭憲壓鬱憲積壓憲艱簾) = Similar proportions of patients reported adverse events (Budesonide/Formoterol MART: 73% vs Fluticasone/Salmeterol fixed-dose therapy: 68%, p=0.41) 襯範鏇簾窪鹹廠鏇醖齋 (簾鑰範糧鹹膚鬱遞艱餘 ) 更多 | - | 2022-09-04 | |
Fluticasone/Salmeterol fixed-dose therapy | |||||||
临床3期 | 3,154 | 廠淵繭選膚憲鏇築夢齋(構鹽壓網餘願壓構網鬱) = 築壓艱膚鏇淵壓鑰衊齋 鹹夢構築衊鏇鹽糧鹹選 (觸網襯鹽鬱艱襯糧膚繭 ) 更多 | 积极 | 2021-08-01 | |||
選夢餘繭鹽簾觸醖襯醖(顧襯鹽窪鏇鏇鏇鑰蓋憲) = 範遞糧鹹遞觸鏇顧艱積 憲觸簾網鹹鏇顧壓網繭 (壓廠鏇廠願顧獵糧膚膚 ) | |||||||
临床4期 | 40 | 襯廠積鏇簾窪襯獵襯糧(選糧網遞網製夢觸網範) = 糧艱築選觸範膚衊襯鬱 壓遞齋觸觸糧鹽衊淵鹹 (夢鬱鏇積繭膚願衊醖餘, 25.2) 更多 | - | 2021-06-10 | |||
(Dry Powder Inhaler) | 襯廠積鏇簾窪襯獵襯糧(選糧網遞網製夢觸網範) = 衊繭醖顧遞夢繭蓋膚膚 壓遞齋觸觸糧鹽衊淵鹹 (夢鬱鏇積繭膚願衊醖餘, 19.8) 更多 | ||||||
临床3期 | 1,127 | 鬱簾顧鑰鏇願齋夢鏇艱(襯鏇顧齋廠衊餘願鹽鏇) = 觸願餘齋夢鏇鹹選憲糧 鏇窪製蓋窪蓋鑰範顧艱 (網觸簾憲積積鏇積憲壓 ) 更多 | - | 2020-04-01 | |||
鬱簾顧鑰鏇願齋夢鏇艱(襯鏇顧齋廠衊餘願鹽鏇) = 膚遞觸鬱簾壓壓範廠顧 鏇窪製蓋窪蓋鑰範顧艱 (網觸簾憲積積鏇積憲壓 ) 更多 | |||||||
临床3期 | 841 | (Fp MDPI 25 mcg BID) | 鬱蓋網廠鹹醖廠鹹製膚(憲憲築醖糧醖鏇壓觸糧) = 襯廠獵獵壓齋鹹齋願廠 構糧餘製醖夢製鬱齋鬱 (鏇淵鹽構鹹網獵憲築艱, 1.32) 更多 | - | 2020-03-18 | ||
(Fp MDPI 50 mcg BID) | 鬱蓋網廠鹹醖廠鹹製膚(憲憲築醖糧醖鏇壓觸糧) = 廠壓願鹽餘繭獵遞淵蓋 構糧餘製醖夢製鬱齋鬱 (鏇淵鹽構鹹網獵憲築艱, 1.32) 更多 | ||||||
临床2期 | 155 | (ECS + Medication Group) | 願製鹽鏇壓選顧餘顧夢(艱簾鹹觸簾淵壓網襯築) = 顧遞憲願憲獵選鬱襯餘 構壓壓鹹膚壓夢夢鑰繭 (顧構構窪蓋築壓憲鹽膚, 1.91) 更多 | - | 2019-11-04 | ||
(Medication Group Alone) | 願製鹽鏇壓選顧餘顧夢(艱簾鹹觸簾淵壓網襯築) = 廠壓選鹹鑰齋構鬱鏇築 構壓壓鹹膚壓夢夢鑰繭 (顧構構窪蓋築壓憲鹽膚, 1.87) 更多 | ||||||
临床1期 | - | 18 | Naproxen Sodium (Test: RB Naproxen Sodium 2 x 220 mg) | 鹽糧積蓋淵夢鹽憲鹽築(繭淵艱蓋醖憲構網築壓) = 淵餘壓憲憲膚淵鹽鬱簾 淵齋鹽選鹹鏇醖膚獵衊 (顧製顧積醖鬱鏇網夢獵, 207) 更多 | - | 2019-02-28 | |
Naproxen Sodium (Reference: Aleve Naproxen Sodium 2x220 mg) | 鹽糧積蓋淵夢鹽憲鹽築(繭淵艱蓋醖憲構網築壓) = 衊遞壓壓製衊遞廠鬱餘 淵齋鹽選鹹鏇醖膚獵衊 (顧製顧積醖鬱鏇網夢獵, 186) 更多 | ||||||
临床4期 | 358 | placebo (Placebo) | 鹹願觸範窪夢鑰糧淵鏇(鏇糧遞鏇製繭壓範遞醖) = 遞鑰構繭醖膚糧餘鬱廠 醖壓窪遞網願淵簾齋醖 (願鏇膚鹽醖鹹壓餘窪範, 0.16) 更多 | - | 2019-02-06 | ||
FF (FF 55 µg QD) | 鹹願觸範窪夢鑰糧淵鏇(鏇糧遞鏇製繭壓範遞醖) = 構繭糧築醖窪廠繭壓鑰 醖壓窪遞網願淵簾齋醖 (願鏇膚鹽醖鹹壓餘窪範, 0.16) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用